Urology Product Preview: Testosterone agent meets efficacy endpoint in phase III studiesDrugs and devices in the pipeline form Clarus Therapeutics, Nymox Pharmaceutical, Bioniche Life Sciences, Repros Therapeutics, BioLight Life Sciences Investments/Micromedic Technologies, Cubist Pharmaceuticals, Takeda Pharmaceutical, H. Lundbeck A/S, Transplant Genomics, Orion, Bayer, and Roche.
AUA 2014: Studies shine light on new PCa tests, TRT safetyIn our “Best of AUA” report, Urology Times’ editors and writers present the AUA annual meeting’s take-home messages in 15 therapeutic areas.
Best of AUA 2014: BPH/LUTSRichard K. Lee, MD, MBA, presents the take home messages on BPH/LUTS from the AUA annual meeting in Orlando, FL.
July 2014 New Urology Products and ServicesNew urology products and services from Symtelligence Medical Informatics, LABORIE, Metamark Genetics, the MediSafe Project, and Olympus
Alpha-blockers top choice for first-line LUTS treatmentMost urologists turn to alpha-blockers as first-line treatment for BPH-related lower urinary tract symptoms, while transurethral resection of the prostate remains the most commonly used surgical modality, according to a recent survey.
BPH surgical modalities safe; some attributes affect outcomesAnalyses of morbidity and mortality after surgery for BPH show that the current major modalities are all safe, but also identify patient attributes associated with an increased risk of complications.
Lumenis launches powerful laser for urologic applicationsLumenis Ltd. has announced the U.S. launch of the Lumenis Pulse 120H Holmium laser platform for a range of urologic applications.
Convective heat system shows efficacy in treating BPHAnalyses of serial magnetic resonance imaging and three-dimensional renderings of those images provide proof of principle for using convective thermal heating to ablate prostate tissue, and early evidence suggests the efficacy and potential clinical advantages of using this novel technology to treat BPH, said first author Lance A. Mynderse, MD, at the European Association of Urology annual congress in Stockholm, Sweden.
BPH research examines inflammation's roleIs inflammation a potential target for the treatment of BPH? New research being presented at the 2014 AUA annual meeting may help answer this question.
Clinical Trial Watch April 2014This list of U.S.-based National Institutes of Health trials is derived from the NIH’s database and includes phase I-IV hypogonadism and BPH trials that are currently recruiting participants.